Biological Trace Element Research

, Volume 17, Issue 1, pp 229–236 | Cite as

Chromium induced clinical improvement in symptomatic hypoglycemia

  • Jørgen Clausen


The present study included 20 patients indicating clinical symptoms of hypoglycemia, of which 19 showed a minimal glucose level in the tolerance curve above 2.2 mmol/L (limit for glucose induced hypoglycemia). This clinical state is defined here as “symptomatic hypoglycemia”. All individuals were studied for effects of a daily intake for three mo of a yeast chromium supplement (125 μg Cr/d). The patients were followed by means of their oral glucose tolerance curve (1 g glucose/kg body wt) and by an interrogation scheme prior to during and after chromium supplementation.

During three mo of chromium supplementation, a decrease was found in the negative part of the glucose tolerance curve, i.e., the part of the curve being below the fasting level in eight patients (40%). However, one mo after treatment, 10 patients out of 13 (77%) showed decreased areas of the negative part of the glucose tolerance curve compared to the values during treatment, and 11 out of 15 (73%) showed decreases in the negative part of the curve when posttreatment data were compared to ante-treatment data.

The subjective clinical effects were followed by means of a questionnaire. Subjectively, the effects of organo-chromium were especially pronounced on chilliness. Thus seven (47%) indicated improvement and two (15%) indicated that the chilliness disappeared. However, trembling, emotional instability, and disorientation symptoms improved as well.

Index Entries

Chromium hypoglycemia glucose tolerance curve organo-chromium treatment 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    K. Schwarz and W. Mertz,Arc. Biochem. Biophys. 85, 292–295 (1959).CrossRefGoogle Scholar
  2. 2.
    L. L. Hopkins, O. Ransome-Kuti, and A. S. Majaj,Amer. J. Clin. Nutr. 21, 203–211 (1986).Google Scholar
  3. 3.
    V. J. Liu and J. S. Morris,Amer. J. Clin. Nutr. 31, 972–976 (1978).PubMedGoogle Scholar
  4. 4.
    E. G. Offenbacher and F. X. Pi-Sunyer,Diabetes 29, 919–925 (1980).PubMedCrossRefGoogle Scholar
  5. 5.
    L. Sherman, A. Glennon, W. J. Breach, G. H. Klomberg, and E. S. Gordon,Metabolism 17, 439–442 (1968).PubMedCrossRefGoogle Scholar
  6. 6.
    V. J. Liu and R. P. Abernathy,Amer. J. Clin. Nutr. 35, 661–667 (1982).PubMedGoogle Scholar
  7. 7.
    G. N. Schrauzer, K. S. Shrestha, T. B. Molenaar, and S. Mead,Biol. Trace Element Res. 9, 79 (1986).CrossRefGoogle Scholar
  8. 8.
    R. A. Anderson,Chromium in Human Health and Disease, Proc. First Meeting Internat. Soc. Trace Element Res., Palm Springs, USA (Dec. 1986).Google Scholar
  9. 9.
    K. Bibow, G. Riis, and B. Salbu,Naeringsforskning 28, 84 (1984).Google Scholar
  10. 10.
    J. Kumpulainen,Proc. Mineral Elements 80. Part I. Helsinki. The Academy of Finland, 263–278, ISBN 951-99301-1-6, (1980).Google Scholar

Copyright information

© The Humana Press Inc 1988

Authors and Affiliations

  • Jørgen Clausen
    • 1
  1. 1.Institute for Life Sciences and ChemistryRoskilde UniversityRoskildeDenmark

Personalised recommendations